舒尼替尼
医学
甲状腺间变性癌
甲状腺癌
舒尼替尼
甲状腺髓样癌
癌症研究
酪氨酸激酶抑制剂
内科学
酪氨酸激酶
血管内皮生长因子
甲磺酸伊马替尼
肿瘤科
癌症
内分泌学
伊马替尼
受体
髓系白血病
血管内皮生长因子受体
作者
Silvia Martina Ferrari,Marco Centanni,Camilla Virili,Mario Miccoli,Paola Ferrari,Ilaria Ruffilli,Francesca Ragusa,Alessandro Antonelli,Poupak Fallahi
标识
DOI:10.2174/0929867324666171006165942
摘要
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors. Methods: We searched the literature on PubMed library. Results: In vitro studies showed that sunitinib targeted the cytosolic MEK/ERK and SAPK/JNK pathways in the RET/PTC1 cell inhibiting cell proliferation and causing stimulation of sodium/iodide symporter (NIS) gene expression in RET/PTC1 cells. Furthermore sunitinib is active in vitro and in vivo against anaplastic thyroid cancer (ATC) cells. Most of the clinical studies report that sunitinib is effective as first- and second-line TKI therapy in patients with advanced dedifferentiated thyroid cancer (DeTC), or medullary thyroid cancer (MTC). Sunitinib 37.5 mg/day is well tolerated, and effective. The most common adverse events include: reduction in blood cell counts (in particular leukocytes), hand-foot skin reaction, diarrhea, fatigue, nausea, hypertension, and musculoskeletal pain. Conclusion: Even if sunitinib is promising in the therapy of differentiated thyroid carcinoma (DTC), until now no phase III studies have been published, and additional prospective researches are necessary in order to evaluate the real efficacy of sunitinib in aggressive thyroid cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI